Thorlund Kristian, Haggstrom Jonas, Park Jay Jh, Mills Edward J
Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Ontario, Canada.
The Bill and Melinda Gates Foundation, Seattle, Washington, USA.
BMJ. 2018 Mar 8;360:k698. doi: 10.1136/bmj.k698.
This article reviews important considerations for researchers who are designing adaptive clinical trials. These differ from conventional clinical trials because they allow and even enforce continual modifications to key components of trial design while data are being collected. This innovative approach has the potential to reduce resource use, decrease time to trial completion, limit allocation of participants to inferior interventions, and improve the likelihood that trial results will be scientifically or clinically relevant. Adaptive designs have mostly been used in trials evaluating drugs, but their use is spreading. The US Food and Drug Administration recently issued guidance on adaptive trial designs, which highlighted general principles and different types of adaptive clinical trials but did not provide concrete guidance about important considerations in designing such trials. Decisions to adapt a trial are not arbitrary; they are based on decision rules that have been rigorously examined via statistical simulations before the first trial participant is enrolled. The authors review important characteristics of adaptive trials and common types of study modifications and provide a practical guide, illustrated with a case study, to aid investigators who are planning an adaptive clinical trial
本文综述了正在设计适应性临床试验的研究人员的重要注意事项。这些试验与传统临床试验不同,因为它们允许甚至强制在收集数据时对试验设计的关键组成部分进行持续修改。这种创新方法有可能减少资源使用、缩短试验完成时间、限制将参与者分配到较差的干预措施,并提高试验结果具有科学或临床相关性的可能性。适应性设计大多用于评估药物的试验,但它们的应用正在扩大。美国食品药品监督管理局最近发布了关于适应性试验设计的指南,该指南强调了一般原则和不同类型的适应性临床试验,但没有提供关于设计此类试验的重要注意事项的具体指导。调整试验的决定并非随意做出;它们基于在招募第一名试验参与者之前通过统计模拟进行严格审查的决策规则。作者回顾了适应性试验的重要特征和常见的研究修改类型,并通过一个案例研究提供了一份实用指南,以帮助正在计划进行适应性临床试验的研究人员。